Trichostatin A (TSA)

For research use only. Not for use in humans.

目录号:S1045 中文名称:曲古柳菌素A

Trichostatin A (TSA) Chemical Structure

CAS No. 58880-19-6

Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Trichostatin A (TSA)发表文献150篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系,包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖,平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系,抑制HDAC活性,平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同,Trichostatin A 抑制这些HDACs,且抑制程度相似, IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞,通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体,而诱导转化生长因子βⅡ型受体(TβRII) 表达,复合体与TβRII 启动子的DNA片段结合,伴随着Sp1乙酰化,且与复合体相关的HDAC数理全部降低。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NWHqe21WTnWwY4Tpc44hSXO|YYm= NXe2RldpOC55zszN MVGyOIg> MkPC[ZRp[W6xbB?= NH[0TZBmdmijbnPld{BGVmGFIHHj[ZR6dGG2aX;uJIFv\CCrbnPy[YF{\XNiRV7hR{Bi[nWwZHHuZ4UhcW5idHjlJJRwfGGuIHPlcIwhdHm|YYTlJIFv\CCjdDD0bIUh[2WubDDzeZJn[WOn MUGyOVc5PzB5OR?=
TE13 NYjrOZNOTnWwY4Tpc44hSXO|YYm= MXqwMlPPxE1? M{j0cFI1cA>? MYj1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= NF\KV|YzPTV5OU[2OS=>
TE13 Mn3FRZBweHSxc3nzJGF{e2G7 MUKwMlPPxE1? M1roO|I1cA>? M1\HbYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? M3TsSVI2PTd7Nk[1
MEFs NYjoVGN2TnWwY4Tpc44hSXO|YYm= Mn:3Oe69VQ>? NHzSdnEyPmh? NE\GeItqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? NYD3W3dpOjV2OEK2N|Q>
SW480  NGT3VmxHfW6ldHnvckBCe3OjeR?= NHnweosxNjIQvF2= MmHwOFhp MXjEUXNQ Mn;MdoV3\XK|ZYOgSW1V M2jWe|I2PDN2OUm3
PC3  MU\GeY5kfGmxbjDBd5NigQ>? MornNE4y|ryP MVi0PIg> M1\TdWROW09? MWLy[ZZmenOnczDFUXQ> M1TIPFI2PDN2OUm3
SW480  NETHOplHfW6ldHnvckBCe3OjeR?= MkDRNE4y|ryP M4\Fb|Q5cA>? NVraZmxKTE2VTx?= NGn6b|ZifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= M2LOO|I2PDN2OUm3
PC3  M1;kS2Z2dmO2aX;uJGF{e2G7 MnLMNE4y|ryP M1nOUlQ5cA>? M2\EPGROW09? M4HETYF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= NY\DcI1GOjV2M{S5PVc>
SW480  Ml\OSpVv[3Srb36gRZN{[Xl? MmTxNE4y|ryP NEjRWVY1QGh? MnTjSG1UVw>? MnLUbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? MUKyOVQ{PDl7Nx?=
PC3  NXXi[2Z6TnWwY4Tpc44hSXO|YYm= Mn7KNE4y|ryP NXHrdno4PDiq M1fuUWROW09? M1HXeYlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? NYHmdVZxOjV2M{S5PVc>
A431 M1;wSGFxd3C2b4Ppd{BCe3OjeR?= MnrSNk8yOC93MD:xNFBvVQ>? MYG0PIg> MUPEUXNQ MV\pcohq[mm2czD0bIUh[2WubDDndo94fGh? MlXiNlU{PzFyNkm=
A431 MXHGeY5kfGmxbjDBd5NigQ>? NWHONZdrPTCwTR?= NUHKeYtZOi94L{GyM|I1cA>? M{nqPWROW09? MnfUZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w Mnz2NlU{PzFyNkm=
MDA-MB-231 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H2cFAuPjBybl2= NWP3d|ZUOjSq MnTaSG1UVw>? M2jRVGlEPTBib3[gNVAxdk1? M4DyTlI2OTl{N{Kx
MCF7 NUC2S|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTWW45rOC14MEDuUS=> M3[1VlI1cA>? MYTEUXNQ NU\uZ3NVUUN3MDDv[kA4PW6P MnP5NlUyQTJ5MkG=
SKOV-3 MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\zepcyNTFyzszN NHvwVIwzPGh? M32yXWROW09? MWfJR|UxKG:oIEWuOu69VQ>? NI\Kc4QzPTF4OUS5NS=>
A549 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm5NU0yOM7:TR?= MYmyOIg> MYnEUXNQ M3Lk[WlEPTBib3[gN{4z|ryP NEXJfowzPTF4OUS5NS=>
SKOV-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzPNE4yNTIQvF2= NUXDNoRWPDiq M3HYN2ROW09? NUXpNnVlUUN3MDDv[kAxNjgQvF2= NEjNXHEzPTF4OUS5NS=>
A549 NWfqfVVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGwMlEuOc7:TR?= NYG2NJhxPDiq M33RXWROW09? NIXNd3lKSzVyIH;mJFAvOjkQvF2= MViyOVE3QTR7MR?=
SKOV-3 M4jOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2wNE4xOS1yLkpOwG0> NIe5Tm44Omh? NEjaTW5FVVOR Mln6TWM2OCCxZjCwMlMz|ryP MmDyNlUyPjl2OUG=
A549 NFfvXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPUXVUxNjBzLUCuPe69VQ>? NYnUU5kzPzKq NEL3UGdFVVOR NUHoT217UUN3MDDv[kAxNjB4zszN NVfvcY1oOjVzNkm0PVE>
HeLa NF3MeYRHfW6ldHnvckBCe3OjeR?= MXKyOVBvVQ>? MnnQNVZp NX;BSJdRTE2VTx?= M4i5RYlv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= NHO5[JkzPTFzNk[4PC=>
CNE2 NGHvd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixNFAuPjBybl2= MkfZNlQwPDhxN{Lo NEDlbGtqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXOydJR3OjR7Nkm5NFE>
PC3 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XYd|ExOC1zMECwcm0> NW\sN4FrOjSq M1vTXWlEPTBib3[gN|Axdk1? MoqxNlQ5PTR4NUi=
LNCaP MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\CNVAxNTFyMEDuUS=> NEHze2EzPGh? NYDD[oVPUUN3MDDv[kA{ODCwTR?= NV;ESoJ6OjR6NUS2OVg>
HeLa  MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\tb|gz|ryP MUe0PIg> NGC2Omll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl MmLxNlQ5PDZzM{W=
HMEC-1  NHPIOmFHfW6ldHnvckBCe3OjeR?= MXSzNFBvVQ>? M3;BdFI1cA>? Ml;IbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> MXiyOFcyODZ|MR?=
HeLa NI\1[VdHfW6ldHnvckBCe3OjeR?= MWGxcW0> MVmwMlVp NXq2VGxG[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 MVWyOFcxPzR5NB?=
ACP02 NGDVVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q0[FI2OC9|NUCvOVAxdk1? NUn5U3E6OjSq M4rwSYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NFX4[FMzPDZ4OEW0Oy=>
ACP03 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT0b|QzPTBxM{WwM|UxOG6P MWeyOIg> NEnBZ2hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MlL5NlQ3Pjh3NEe=
U87 GBM NH3UcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hblExOC9|MECvOVAxKG6P NEj3ZXY4OiCq MV[xNFAmKGW2aHHuc4w> Mni4doVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl NFTsZ4gzPDR4NEi0NS=>
U87 GBM MVvGeY5kfGmxbjDBd5NigQ>? NW\aNWlqOTByL{WwNEBPdQ>? M13wSFQ5KGh? NIrZUFAyODBnIHX0bIFvd2x? M3fONmlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? M1\XblI1PDZ2OESx
RPE M3TQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKwMlIwOC52L{CuPE8yKM7:TR?= NHPGb3gzPC92OD:3NkBp MkLlSG1UVw>? NIDQUGlqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? NF61Z|EzPDR3Nk[wNi=>
HT29  NEXIR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexPFAhdk1? M3vJTFczKGh? MXnJR|UxKG:oIEG4NEBvVQ>? MnzsNlQ{Pjh{NkW=
hMSCs NH;ndXdHfW6ldHnvckBCe3OjeR?= M2H5SFYvOjVibl2= NFz1OmMzPCCq M1\ncmROW09? MX\zeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| Mn;DNlQ{OTJ|NU[=
Huh7  NY\3eXhjTnWwY4Tpc44hSXO|YYm= M1jxRVAvOS9yLkWvNU4xKM7:TR?= NH\XbWIzPGh? NEHxT4x{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= M2[3R|I1OjZ7Nkey
SKOV3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XsXFAvODVvMjFOwG0> NWfQfVBoOTBxMkSvOFghcA>? MUnEUXNQ M3u4Zo1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NW\SUnJmOjR{MkO4NFE>
A2780 NVv0TGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGwMlA2NTJizszN NFTxT4wyOC9{ND:0PEBp NG\HSVBFVVOR NF\TTHNu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MmjoNlQzOjN6MEG=
SRA01/04  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXLNE4zKM7:TR?= MmfsOFghcA>? M2fSTmROW09? M4nVeZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ M4Kzc|I1OTV5OEe4
HLEB3 M4H5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDHNE4zKM7:TR?= MnzoOFghcA>? MkjrSG1UVw>? NGq2cXp{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? MV:yOFE2Pzh5OB?=
SRA01/04  NIi5c|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu0cYkxNjRxMD64JO69VQ>? MXS0PEBp NFv4VZVFVVOR MULpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Ml:wNlQyPTd6N{i=
HLEB3 NFjZcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTENE41NzBwODFOwG0> MXS0PEBp NIXQVlRFVVOR NEX2R2lqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NWrENZB5OjRzNUe4O|g>
HCT116 M{ftd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXewMlIh|ryP MkD5NVIhcA>? NG[1cmRmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JJJi\GmjdHnvci=> Mn[yNlQyOjJ{M{G=
CA46 NHzCSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\Zc3Z6Oy94L{GyM|I1NzR6IH7N NHrvZnI1QCCq NGPR[5hqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi NILGflAzPDB4NEm1NS=>
PMNs MljmSpVv[3Srb36gRZN{[Xl? NW\hSJpbOzBibl2= MlnkOFghcA>? NEDoZW5qdmirYnn0d{Bm\m[ncn;jfZRwe2m|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk> MWeyN|k5QDZzNx?=
H1299 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M371fFHDqM7:TdMg M3fZOFI1NzR6L{eyJIg> MlrW[ZRp[W6xbB?= NWLTXJZwcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq M{jZcVI{QTF4NkC5
A549 M1r5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\yPVAvOjVxMD61M|Eh|ryP MXWyOE81QC95MjDo MmK3[ZRp[W6xbB?= NUjqW2V6cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MV2yN|g3Pzl7MR?=
H1299 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHCNE4zPS9yLkWvNUDPxE1? NHzjcFkzPC92OD:3NkBp NEfLToVmfGijbn;s M3;OSYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MWGyN|g3Pzl7MR?=
A549 NU\WUZF[SXCxcITvd4l{KEG|c3H5 NIjyRpUxNjVxMTFOwG0> NY\mOohuPDhiaB?= MULleIhidm:u NYHL[VdncW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mn3kNlM5Pjd7OUG=
H1299 M{n0eWFxd3C2b4Ppd{BCe3OjeR?= NYj2XYp[OC53L{Gg{txO NW\6UGlqPDhiaB?= NYPuW40z\XSqYX7vcC=> MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NVHhO|JjOjN6Nke5PVE>
SUM149PT MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXMbFMzNzdwNT:xNEDPxE1? MVq0PEBp M2[2VWROW09? NGXC[WtqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= MVOyN|c6OjZ|OB?=
SUM190PT NEn1WHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS2OVAwOTByL{K1NEBvVQ>? MWG0PEBp MmfkSG1UVw>? NV7JeVR3cW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 NWLrcJV7OjN5OUK2N|g>
HCT1 M3G5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHOT4gxNjJxMT6wM|UvOCEQvF2= M33UcVEzNzJ2L{O2M|Q5KGh? M{m2XIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy Mn[xNlM4PzByMEC=
Lovo NHS5cVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HzS|AvOi9zLkCvOU4xKM7:TR?= NXLyWnRTOTJxMkSvN|YwPDhiaB?= MlLQbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NVTITnhrOjN5N{CwNFA>
AGS Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S5O|AvODF3LUGg{txO MXy3NkBp NVntOGpWcW6mdXPld{Bk\WyuIHTlZZRpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NVXJUY8yOjN5NEWwNlQ>
Huh7 NH\JRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TuPVEh|ryP NV\kSpJ[OjRiaB?= MUjEUXNQ M4H3fJJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh MUKyN|Y1Ozl|Mx?=
ECC1 MnLRSpVv[3Srb36gRZN{[Xl? MVi1NFAhdk1? NWjNS2llPSCm NF;tfIVFVVOR NGjRc2VqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MYeyN|U{ODd4OR?=
HEC1A NIDlUVJHfW6ldHnvckBCe3OjeR?= M4qzSFUxOCCwTR?= NWXyZVJGPSCm NIfwXW9FVVOR Mn3lbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? Mn7INlM2OzB5Nkm=
EN1 NUjGdno1TnWwY4Tpc44hSXO|YYm= NVHLOml[PTByIH7N MmKxOUBl M{ToSWROW09? MWHpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NWjK[3FWOjN3M{C3Olk>
MFE296 NYrPeIY6TnWwY4Tpc44hSXO|YYm= MoPHOVAxKG6P M{HBVFUh\A>? MUjEUXNQ M3v6Oolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NYTFS|JVOjN3M{C3Olk>
HASMCs MYrGeY5kfGmxbjDBd5NigQ>? NEW1XVExNTVyMDDuUS=> NILYcoI3KGR? Mmfr[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> MWWyN|UyQDR4Nx?=
U373 Mn\OSpVv[3Srb36gRZN{[Xl? NHLlWWcxNjJ3L{CuOU8yKM7:TR?= NWnsWYFFOjRiaB?= MoTObY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? M2eyblI{PDd2MUex
ARN8  MWPGeY5kfGmxbjDBd5NigQ>? MYmwMlA2NTJizszN MmT0NlQhcA>? NHLzR4Vz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? MkfzNlM1PzB3NEC=
MCF7 NW\pfFA2TnWwY4Tpc44hSXO|YYm= MWOwMlA2NTJizszN MmTlNlQhcA>? MlTkdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> MlXnNlM1PzB3NEC=
H1299  M4fLXmZ2dmO2aX;uJGF{e2G7 M{P0flAvOzQkgKOxxsDDvU1? MlfsNlQwPDhiaB?= MlK0SG1UVw>? MX\pcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 NEOwSFgzOzR4MUm3OS=>
H1299 M1rxc2Z2dmO2aX;uJGF{e2G7 NF\lXXoxNjVizszN MnPYOFghcA>? M{[zS2ROW09? NFvidWhqdmirYnn0d{B1cGVibXnndoF1d3K7IIDveIVvfGmjbDDjc41jcW6nIIfpeIghe2muaXLpcolv NFXvZ4UzOzR4MUm3OS=>
H1299 NIT4fJJHfW6ldHnvckBCe3OjeR?= MUewMlUh|ryP MUe0PEBp NG[ze3dFVVOR NH\ZcWVqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= M4K5flI{PDZzOUe1
MG-63  NXnDUnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmwMlMh|ryP NVnEfplMOTJvOU[gbC=> MlGySG1UVw>? MlSzbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MXWyN|Q2OThzNx?=
LM8 NGSwdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILyPFMxNjNizszN M17pUFEzNTl4IHi= MoHwSG1UVw>? NXe0ZpBTcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> M4jve|I{PDVzOEG3
K562 NUf1UZZMTnWwY4Tpc44hSXO|YYm= M3jHZlAvPSEQvF2= MnjKNlQhcA>? NUS1Nmo2\XSqYX7vcC=> M2PtOoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv MnjlNlM1OzB7NUe=
HEL NWj4bGt1TnWwY4Tpc44hSXO|YYm= NXHXdVJ2OC53IN88US=> NYfNcZhNOjRiaB?= MkD3[ZRp[W6xbB?= NG\zSHJl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NIPrU5YzOzR|MEm1Oy=>
HL60 M1PqUGFxd3C2b4Ppd{BCe3OjeR?= MXyxJO69VQ>? M4LVSlI1KGh? M1rCOolv\HWlZYRCpINmdGxiZHXheIg> NWWxWZdwOjN2MEC1NVk>
KG1 NYLv[Y9vSXCxcITvd4l{KEG|c3H5 NYTsc|NHOSEQvF2= NFfaVJMzPCCq M2njcolv\HWlZYRCpINmdGxiZHXheIg> M2K3bFI{PDByNUG5
Kazumi NF;2PYhCeG:ydH;zbZMhSXO|YYm= NILMbpkyKM7:TR?= MWiyOEBp MWjpcoR2[2W|wrDj[YxtKGSnYYTo NVPjfFdMOjN2MEC1NVk>
K562 MWTBdI9xfG:|aYOgRZN{[Xl? NWPqNY06OSEQvF2= M3rOVlI1KGh? M1Xz[4lv\HWlZYRCpINmdGxiZHXheIg> M4TTZlI{PDByNUG5
THP1 MlvoRZBweHSxc3nzJGF{e2G7 NXfjfmRqOSEQvF2= NUTKWFF5OjRiaB?= M4fBV4lv\HWlZYRCpINmdGxiZHXheIg> Mn;iNlM1ODB3MUm=
SH-SY5Y MkfoSpVv[3Srb36gRZN{[Xl? NIfKVpQzPTBibl2= NHrBSI4yPiCq NUDlUnkz[2ijbnfld{BmgHC{ZYPzbY9vKHCjdITldo4hd2ZiZ3Xu[ZMhcW64b3z2[YQhcW5iY3jvcIV{fGW{b3ygd5lvfGinc3nzMEB2eHSja3WgZY5lKGWoZnz1fC=> MlPxNlM{OjZ2MkK=
HEK293 NWPxd3gyTnWwY4Tpc44hSXO|YYm= MkXxNUDDvU4EoB?= MVKxPEBpyqB? M1uzZYlvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? NH6zNGkzOzJ6NEi0PC=>
HTK MU\GeY5kfGmxbjDBd5NigQ>? M2PiblQxOCCwTR?= MYO3NkBp M2foeIlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> M4n5RVI{Ojh2MECy
HTK MUTGeY5kfGmxbjDBd5NigQ>? NXfmSo44OTByLUiwNI5O MmLxO|IhcA>? MX\icI9kc3NiVFfGMe6z6oDVSX7keYNm\CCUT2OgZY5lKEh{T{NCpGFk[3WvdXzheIlwdg>? NIjRZpYzOzJ6NECwNi=>
Caco-2  M4n3RWZ2dmO2aX;uJGF{e2G7 NVXH[|hGOSEEtV5CpC=> NFXOb5MzPCCq MmPT[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w MWqyN|E6PTB5MB?=
HeLa NXH2S4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvuUW5WOTByIH7N NIO1[W8zPCCq MoGzSG1UVw>? NH\K[GxKSzVyIH;mJFExOG6P NYSxZ5FNOjNzNkW3OFg>
HeLa MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXq0NEBvVQ>? NEToU3o1QCCq MkD3SG1UVw>? MXfJR|UxKG:oIESwcm0> NE\aO3czOzF4NUe0PC=>
HeLa NF:3VIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWyNEBvVQ>? NGX5Olc4OiCq NV;YZVhPTE2VTx?= NUPyV295UUN3MDDv[kAzOG6P MUWyN|E3PTd2OB?=
HeLa NU[3V3JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M133O|ExNzNyL{WwJI5O MnfBO|IhcA>? Mn\WSG1UVw>? Mo\QbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 M{S0TFI{OTZ3N{S4
MDA-MB-231 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnh[mozPS12MECgcm0> NF\yTZc1QCCq NV7YTYMzUUN3MDDv[kAzPjNwMn7NxsA> MYKyN|A2PTF7OB?=
MCF-7  Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\0flI2NTRyMDDuUS=> MVK0PEBp NF;UWGVKSzVyIH;mJFIzOC52bl2= MVOyN|A2PTF7OB?=
ECC-1  M3HZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH5[osyODBibl2= NWDmXFdzOjRiaB?= Mluy[ZRp[W6xbB?= NUnWZXRPcW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl NUPMVVRyOjNyMki4NFM>
HEC-1A M2W4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPre2RGOTByIH7N MViyOEBp NW\Z[FVU\XSqYX7vcC=> M2CxXolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= Mn7uNlMxOjh6MEO=
NHAC-kn Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:5NVAwOTByL{WwNEBvVQ>? NHXYRWsyOiCq M3ewN2ROW09? Ml\vTWM2OCCxZjC1NFBvVQ>? Mm\UNlMxOTd6N{G=
A549 NIDheJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLofHFpOjVyIH7N NGrzfGQ3NTd{IHi= MUHEUXNQ MoG5Z4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> MXiyNlk6PDd6MB?=
MG-63 M2HrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfocGs{ODBibl2= MorhNVIhcA>? MWjEUXNQ MlP4bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? MWqyNlc6QTN|OB?=
MG-63 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvKSmM{ODBibl2= NFTNclIzPCCq Mn\pSG1UVw>? Mni5bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>? MUSyNlc6QTN|OB?=
MG-63 M{PE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorHN|AxKG6P MYi0PEBp NHTkUIJFVVOR NGG1RZBqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn NYnweJM4OjJ5OUmzN|g>
HL60  M3WxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWxOVAuOzVyIH7N NIXDSFMzPCCq M{KwT4lv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NITlPGMzOjd3M{ezPS=>
U937 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxOVAuOzVyIH7N NEDZUnIzPCCq NF;WNYhqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O NFXL[XgzOjd3M{ezPS=>
SCC-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PvZ|IxOC1|MkCwJI5O MmTzNVIwOjRxNEigbC=> NULkXW1XTE2VTx?= MX;pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M4jKclIzPTV{M{Kx
U87  NH\ib|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX3NVAxNTNyMDDu[y=> NXLBVGdtOjRiaB?= M4rue4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A4OiViIHH0JFIxOG6p MUGyNlI4ODh2OR?=
K562 M4Txb2Z2dmO2aX;uJGF{e2G7 MU[xJO69VQ>? NHLpbGsyOiCq NXHseWJGTE2VTx?= MWflcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= NVXVfIRqOjJzN{mxPVg>
Reh NGjOTGRHfW6ldHnvckBCe3OjeR?= NGTDdocxNjNxMTFOwG0> MX2xNkBp NGPyfHNFVVOR Mnzq[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= NXjtfVlkOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型,持续处理4周,具有有效的抗癌活性,即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症(SMA)模型鼠,导致乙酰化的 H3 和 H4组蛋白水平提高,也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠,促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时,或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火,然后使用600 μL 乙酸乙酯进行抽提,通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据,绘制合适的剂量反应曲线,而测定IC50。
细胞实验:[1]
- 合并
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3

CAS号 58880-19-6
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa February 27 2020 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID